The Experts below are selected from a list of 48429 Experts worldwide ranked by ideXlab platform

Norio Araki - One of the best experts on this subject based on the ideXlab platform.

  • clinical outcomes of a phase i ii study of 48 gy of stereotactic Body radiotherapy in 4 fractions for primary lung cancer using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2005
    Co-Authors: Yasushi Nagata, Takashi Mizowaki, Michihide Mitsumori, K Takayama, Yukinori Matsuo, Yoshiki Norihisa, Takashi Sakamoto, M Sakamoto, Keiko Shibuya, Norio Araki
    Abstract:

    Purpose: To evaluate the clinical outcomes of 48 Gy of three-dimensional stereotactic radiotherapy in four fractions for treating Stage I lung cancer using a stereotactic Body Frame. Methods and Materials: Forty-five patients who were treated between September 1998 and February 2004 were included in this study. Thirty-two patients had Stage IA lung cancer, and the other 13 had Stage IB lung cancer where tumor size was less than 4 cm in diameter. Three-dimensional treatment planning using 6–10 noncoplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume >20 Gy. All patients were irradiated using a stereotactic Body Frame and received four single 12 Gy high doses of radiation at the isocenter over 5–13 (median = 12) days. Results: Seven tumors (16%) completely disappeared after treatment (CR) and 38 tumors (84%) decreased in size by 30% or more (PR). Therefore, all tumors showed local response. During the follow-up of 6–71 (median = 30) months, no pulmonary complications greater than an National Cancer Institute-Common Toxicity Criteria of Grade 3 were noted. No other vascular, cardiac, esophageal, or neurologic toxicities were encountered. Forty-four (98%) of 45 tumors were locally controlled during the follow-up period. However, regional recurrences and distant metastases occurred in 3 and 5 of T1 patients and zero and 4 of T2 patients, respectively. For Stage IA lung cancer, the disease-free survival and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage IB lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively. Conclusion: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereotactic Body Frame is useful for the treatment of Stage I lung tumors.

  • clinical outcomes of 3d conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, Keisuke Sasai, Yuta Shibamoto
    Abstract:

    Abstract Purpose : This study was performed to evaluate the clinical outcomes of three-dimensional (3D) conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic Body Frame. Methods and Materials : Forty patients who were treated between July 1998 and November 2000 and were followed for >10 months were included in this study. Of the 40 patients, 31 had primary lung cancer and 9 had metastatic lung cancer. The primary lung cancer was staged as T1N0M0, T2N0M0, and T3N0M0 in 19, 8, and 4 patients, respectively. The primary sites of metastatic lung cancer were the colon in 4, tongue in 2, and osteosarcoma, lung cancer, and hepatocellular carcinoma in 1 each. 3D treatment planning was performed to maintain the target dose homogeneity within 15% and to decrease the irradiated lung volume from >20 Gy to Results : The initial 3 patients received 40, and the remaining 37 patients received 48 Gy after dose escalation. Of the 33 tumors followed >6 months, 6 tumors (18%) disappeared completely after treatment. Twenty-five tumors (76%) decreased in size by 30% or more after treatment. Therefore, 31 tumors (94%) showed a local response. During the follow-up of 4–37 months (median 19), no pulmonary complications greater than National Cancer Institute-Common Toxicity Criteria Grade 2 were noted. Of the 16 patients with histologically confirmed T1N0M0 primary lung cancer who received 48 Gy, all tumors were locally controlled during the follow-up of 6–36 months (median = 19). In 9 tumors with lung metastases that were irradiated with 48 Gy in total, 2 tumors did not show a local response. Finally, 3 tumors (33%) with lung metastases relapsed locally at 6–12 months (median 7) after treatment during the follow-up of 3–29 months (median 18). Conclusion : 3D conformal hypofractionated single high-dose radiotherapy of 48 Gy in 4 fractions using a stereotactic Body Frame was useful for the treatment of lung tumors.

  • Three-dimensional conformal radiotherapy for extracranial tumors using a stereotactic Body Frame
    Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, S. Yano, Yuko Koga
    Abstract:

    This paper was reviewed to evaluate the feasibility of three-dimensional (3-D) conformal radiotherapy for extracranial tumors, especially for solitary lung tumors using a stereotactic Body Frame. To extend the technique of stereotactic irradiation for intracranial tumors, accurate Body fixation and regulation of internal target motion are essential. In our study, a stereotactic Body Frame was used, and daily setup accuracy was verified. As a result, its setup accuracy was maintained within 0-8.5 mm (Ave=2.5mm). In our initial clinical experiences for thirty-two patients with 6-10 non-coplanar static beams, forty or 48 Gy was irradiated. During the follow-up of 4-27 (Average=11) months, twenty-nine (94%) tumors were locally controlled without any symptomatic complications. Recently, respiratory-gated irradiation systems, CT-linac systems, a real-time tumor tracking system, Cyber-knife, and C-arm linac were developed. With all these techniques, stereotactic irradiation for extracranial tumors are future direction of three-dimensional conformal radiotherapy.

Yasushi Nagata - One of the best experts on this subject based on the ideXlab platform.

  • clinical outcomes of a phase i ii study of 48 gy of stereotactic Body radiotherapy in 4 fractions for primary lung cancer using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2005
    Co-Authors: Yasushi Nagata, Takashi Mizowaki, Michihide Mitsumori, K Takayama, Yukinori Matsuo, Yoshiki Norihisa, Takashi Sakamoto, M Sakamoto, Keiko Shibuya, Norio Araki
    Abstract:

    Purpose: To evaluate the clinical outcomes of 48 Gy of three-dimensional stereotactic radiotherapy in four fractions for treating Stage I lung cancer using a stereotactic Body Frame. Methods and Materials: Forty-five patients who were treated between September 1998 and February 2004 were included in this study. Thirty-two patients had Stage IA lung cancer, and the other 13 had Stage IB lung cancer where tumor size was less than 4 cm in diameter. Three-dimensional treatment planning using 6–10 noncoplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume >20 Gy. All patients were irradiated using a stereotactic Body Frame and received four single 12 Gy high doses of radiation at the isocenter over 5–13 (median = 12) days. Results: Seven tumors (16%) completely disappeared after treatment (CR) and 38 tumors (84%) decreased in size by 30% or more (PR). Therefore, all tumors showed local response. During the follow-up of 6–71 (median = 30) months, no pulmonary complications greater than an National Cancer Institute-Common Toxicity Criteria of Grade 3 were noted. No other vascular, cardiac, esophageal, or neurologic toxicities were encountered. Forty-four (98%) of 45 tumors were locally controlled during the follow-up period. However, regional recurrences and distant metastases occurred in 3 and 5 of T1 patients and zero and 4 of T2 patients, respectively. For Stage IA lung cancer, the disease-free survival and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage IB lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively. Conclusion: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereotactic Body Frame is useful for the treatment of Stage I lung tumors.

  • clinical outcomes of 3d conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, Keisuke Sasai, Yuta Shibamoto
    Abstract:

    Abstract Purpose : This study was performed to evaluate the clinical outcomes of three-dimensional (3D) conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic Body Frame. Methods and Materials : Forty patients who were treated between July 1998 and November 2000 and were followed for >10 months were included in this study. Of the 40 patients, 31 had primary lung cancer and 9 had metastatic lung cancer. The primary lung cancer was staged as T1N0M0, T2N0M0, and T3N0M0 in 19, 8, and 4 patients, respectively. The primary sites of metastatic lung cancer were the colon in 4, tongue in 2, and osteosarcoma, lung cancer, and hepatocellular carcinoma in 1 each. 3D treatment planning was performed to maintain the target dose homogeneity within 15% and to decrease the irradiated lung volume from >20 Gy to Results : The initial 3 patients received 40, and the remaining 37 patients received 48 Gy after dose escalation. Of the 33 tumors followed >6 months, 6 tumors (18%) disappeared completely after treatment. Twenty-five tumors (76%) decreased in size by 30% or more after treatment. Therefore, 31 tumors (94%) showed a local response. During the follow-up of 4–37 months (median 19), no pulmonary complications greater than National Cancer Institute-Common Toxicity Criteria Grade 2 were noted. Of the 16 patients with histologically confirmed T1N0M0 primary lung cancer who received 48 Gy, all tumors were locally controlled during the follow-up of 6–36 months (median = 19). In 9 tumors with lung metastases that were irradiated with 48 Gy in total, 2 tumors did not show a local response. Finally, 3 tumors (33%) with lung metastases relapsed locally at 6–12 months (median 7) after treatment during the follow-up of 3–29 months (median 18). Conclusion : 3D conformal hypofractionated single high-dose radiotherapy of 48 Gy in 4 fractions using a stereotactic Body Frame was useful for the treatment of lung tumors.

  • Three-dimensional conformal radiotherapy for extracranial tumors using a stereotactic Body Frame
    Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, S. Yano, Yuko Koga
    Abstract:

    This paper was reviewed to evaluate the feasibility of three-dimensional (3-D) conformal radiotherapy for extracranial tumors, especially for solitary lung tumors using a stereotactic Body Frame. To extend the technique of stereotactic irradiation for intracranial tumors, accurate Body fixation and regulation of internal target motion are essential. In our study, a stereotactic Body Frame was used, and daily setup accuracy was verified. As a result, its setup accuracy was maintained within 0-8.5 mm (Ave=2.5mm). In our initial clinical experiences for thirty-two patients with 6-10 non-coplanar static beams, forty or 48 Gy was irradiated. During the follow-up of 4-27 (Average=11) months, twenty-nine (94%) tumors were locally controlled without any symptomatic complications. Recently, respiratory-gated irradiation systems, CT-linac systems, a real-time tumor tracking system, Cyber-knife, and C-arm linac were developed. With all these techniques, stereotactic irradiation for extracranial tumors are future direction of three-dimensional conformal radiotherapy.

Stanley Chien - One of the best experts on this subject based on the ideXlab platform.

  • SU‐FF‐T‐395: Stereotactic Body Frame Apparatus
    Medical Physics, 2006
    Co-Authors: Lech Papiez, R Timmerman, Stanley Chien
    Abstract:

    Purpose: To improve immobilization and setup accuracy of patients undergoing extracranial radiosurgery(SBRT therapy). Make possible SBRTtreatments of oversized patients. Method and Materials: Advantages of Frame based extracranial therapy are: (i) Reduction of the imprecision of positioning. (ii) Reduction of the geometrical treatment error in case Frameless delivery tools malfunction. (iii) Efficient and reliable method of abdomen pressure for decreasing tissue motion effects. (iv) Comfort positioning that diminishes Body movements caused by fatigue or pain manifest for an extended period of treatment. To utilize advantages of Frame based approach to extracranial radiotherapy, and to also address some of the shortcomings of the existing immobilization devices, the new stereotactic Body Frame (SBF) has been constructed. The Frame has been designed to be light, strong and rigid. The Frame allows minimizing the disturbance of the penetrating radiation and facilitates its easy handling by therapists/physicists/physicians. The Frame displays necessary rigidity to minimize errors associated with potential deformation. For these reasons the Frame, as well as all accessories, have been all built from carbon fiber. The system is additionally equipped with the multimodal marker sources allowing synchronizing images of Frame and patient Body from a variety of imaging platforms. In summary, the new SBF Frame allows dealing effectively with: (i) patient size limitations, (ii) abdominal pressure adjustments and pressure monitoring, (iii) stability and positioning accuracy of the measuring arc, (iv) fixation mechanism connecting Frame to the couch (to utilize automatic couch motion capability), (v) facilitating extended distance SAD treatments.Results: The device satisfying considerations discussed above have been constructed. The device's parameters and accessories have been evaluated and its clinical applications defined and verified. Conclusion: The new carbon fiber immobilization Frame for SBRTtreatments is ready for clinical evaluation. Conflict of Interest: Research supported by a grant from Varian Medical Systems.

Takashi Mizowaki - One of the best experts on this subject based on the ideXlab platform.

  • clinical outcomes of a phase i ii study of 48 gy of stereotactic Body radiotherapy in 4 fractions for primary lung cancer using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2005
    Co-Authors: Yasushi Nagata, Takashi Mizowaki, Michihide Mitsumori, K Takayama, Yukinori Matsuo, Yoshiki Norihisa, Takashi Sakamoto, M Sakamoto, Keiko Shibuya, Norio Araki
    Abstract:

    Purpose: To evaluate the clinical outcomes of 48 Gy of three-dimensional stereotactic radiotherapy in four fractions for treating Stage I lung cancer using a stereotactic Body Frame. Methods and Materials: Forty-five patients who were treated between September 1998 and February 2004 were included in this study. Thirty-two patients had Stage IA lung cancer, and the other 13 had Stage IB lung cancer where tumor size was less than 4 cm in diameter. Three-dimensional treatment planning using 6–10 noncoplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume >20 Gy. All patients were irradiated using a stereotactic Body Frame and received four single 12 Gy high doses of radiation at the isocenter over 5–13 (median = 12) days. Results: Seven tumors (16%) completely disappeared after treatment (CR) and 38 tumors (84%) decreased in size by 30% or more (PR). Therefore, all tumors showed local response. During the follow-up of 6–71 (median = 30) months, no pulmonary complications greater than an National Cancer Institute-Common Toxicity Criteria of Grade 3 were noted. No other vascular, cardiac, esophageal, or neurologic toxicities were encountered. Forty-four (98%) of 45 tumors were locally controlled during the follow-up period. However, regional recurrences and distant metastases occurred in 3 and 5 of T1 patients and zero and 4 of T2 patients, respectively. For Stage IA lung cancer, the disease-free survival and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage IB lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively. Conclusion: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereotactic Body Frame is useful for the treatment of Stage I lung tumors.

  • clinical outcomes of 3d conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, Keisuke Sasai, Yuta Shibamoto
    Abstract:

    Abstract Purpose : This study was performed to evaluate the clinical outcomes of three-dimensional (3D) conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic Body Frame. Methods and Materials : Forty patients who were treated between July 1998 and November 2000 and were followed for >10 months were included in this study. Of the 40 patients, 31 had primary lung cancer and 9 had metastatic lung cancer. The primary lung cancer was staged as T1N0M0, T2N0M0, and T3N0M0 in 19, 8, and 4 patients, respectively. The primary sites of metastatic lung cancer were the colon in 4, tongue in 2, and osteosarcoma, lung cancer, and hepatocellular carcinoma in 1 each. 3D treatment planning was performed to maintain the target dose homogeneity within 15% and to decrease the irradiated lung volume from >20 Gy to Results : The initial 3 patients received 40, and the remaining 37 patients received 48 Gy after dose escalation. Of the 33 tumors followed >6 months, 6 tumors (18%) disappeared completely after treatment. Twenty-five tumors (76%) decreased in size by 30% or more after treatment. Therefore, 31 tumors (94%) showed a local response. During the follow-up of 4–37 months (median 19), no pulmonary complications greater than National Cancer Institute-Common Toxicity Criteria Grade 2 were noted. Of the 16 patients with histologically confirmed T1N0M0 primary lung cancer who received 48 Gy, all tumors were locally controlled during the follow-up of 6–36 months (median = 19). In 9 tumors with lung metastases that were irradiated with 48 Gy in total, 2 tumors did not show a local response. Finally, 3 tumors (33%) with lung metastases relapsed locally at 6–12 months (median 7) after treatment during the follow-up of 3–29 months (median 18). Conclusion : 3D conformal hypofractionated single high-dose radiotherapy of 48 Gy in 4 fractions using a stereotactic Body Frame was useful for the treatment of lung tumors.

  • Three-dimensional conformal radiotherapy for extracranial tumors using a stereotactic Body Frame
    Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, S. Yano, Yuko Koga
    Abstract:

    This paper was reviewed to evaluate the feasibility of three-dimensional (3-D) conformal radiotherapy for extracranial tumors, especially for solitary lung tumors using a stereotactic Body Frame. To extend the technique of stereotactic irradiation for intracranial tumors, accurate Body fixation and regulation of internal target motion are essential. In our study, a stereotactic Body Frame was used, and daily setup accuracy was verified. As a result, its setup accuracy was maintained within 0-8.5 mm (Ave=2.5mm). In our initial clinical experiences for thirty-two patients with 6-10 non-coplanar static beams, forty or 48 Gy was irradiated. During the follow-up of 4-27 (Average=11) months, twenty-nine (94%) tumors were locally controlled without any symptomatic complications. Recently, respiratory-gated irradiation systems, CT-linac systems, a real-time tumor tracking system, Cyber-knife, and C-arm linac were developed. With all these techniques, stereotactic irradiation for extracranial tumors are future direction of three-dimensional conformal radiotherapy.

Michihide Mitsumori - One of the best experts on this subject based on the ideXlab platform.

  • clinical outcomes of a phase i ii study of 48 gy of stereotactic Body radiotherapy in 4 fractions for primary lung cancer using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2005
    Co-Authors: Yasushi Nagata, Takashi Mizowaki, Michihide Mitsumori, K Takayama, Yukinori Matsuo, Yoshiki Norihisa, Takashi Sakamoto, M Sakamoto, Keiko Shibuya, Norio Araki
    Abstract:

    Purpose: To evaluate the clinical outcomes of 48 Gy of three-dimensional stereotactic radiotherapy in four fractions for treating Stage I lung cancer using a stereotactic Body Frame. Methods and Materials: Forty-five patients who were treated between September 1998 and February 2004 were included in this study. Thirty-two patients had Stage IA lung cancer, and the other 13 had Stage IB lung cancer where tumor size was less than 4 cm in diameter. Three-dimensional treatment planning using 6–10 noncoplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume >20 Gy. All patients were irradiated using a stereotactic Body Frame and received four single 12 Gy high doses of radiation at the isocenter over 5–13 (median = 12) days. Results: Seven tumors (16%) completely disappeared after treatment (CR) and 38 tumors (84%) decreased in size by 30% or more (PR). Therefore, all tumors showed local response. During the follow-up of 6–71 (median = 30) months, no pulmonary complications greater than an National Cancer Institute-Common Toxicity Criteria of Grade 3 were noted. No other vascular, cardiac, esophageal, or neurologic toxicities were encountered. Forty-four (98%) of 45 tumors were locally controlled during the follow-up period. However, regional recurrences and distant metastases occurred in 3 and 5 of T1 patients and zero and 4 of T2 patients, respectively. For Stage IA lung cancer, the disease-free survival and overall survival rates after 1 and 3 years were 80% and 72%, and 92% and 83%, respectively, whereas for Stage IB lung cancer, the disease-free survival and overall survival rates were 92% and 71%, and 82% and 72%, respectively. Conclusion: Forty-eight Gy of 3D stereotactic radiotherapy in 4 fractions using a stereotactic Body Frame is useful for the treatment of Stage I lung tumors.

  • clinical outcomes of 3d conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic Body Frame
    International Journal of Radiation Oncology Biology Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, Keisuke Sasai, Yuta Shibamoto
    Abstract:

    Abstract Purpose : This study was performed to evaluate the clinical outcomes of three-dimensional (3D) conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic Body Frame. Methods and Materials : Forty patients who were treated between July 1998 and November 2000 and were followed for >10 months were included in this study. Of the 40 patients, 31 had primary lung cancer and 9 had metastatic lung cancer. The primary lung cancer was staged as T1N0M0, T2N0M0, and T3N0M0 in 19, 8, and 4 patients, respectively. The primary sites of metastatic lung cancer were the colon in 4, tongue in 2, and osteosarcoma, lung cancer, and hepatocellular carcinoma in 1 each. 3D treatment planning was performed to maintain the target dose homogeneity within 15% and to decrease the irradiated lung volume from >20 Gy to Results : The initial 3 patients received 40, and the remaining 37 patients received 48 Gy after dose escalation. Of the 33 tumors followed >6 months, 6 tumors (18%) disappeared completely after treatment. Twenty-five tumors (76%) decreased in size by 30% or more after treatment. Therefore, 31 tumors (94%) showed a local response. During the follow-up of 4–37 months (median 19), no pulmonary complications greater than National Cancer Institute-Common Toxicity Criteria Grade 2 were noted. Of the 16 patients with histologically confirmed T1N0M0 primary lung cancer who received 48 Gy, all tumors were locally controlled during the follow-up of 6–36 months (median = 19). In 9 tumors with lung metastases that were irradiated with 48 Gy in total, 2 tumors did not show a local response. Finally, 3 tumors (33%) with lung metastases relapsed locally at 6–12 months (median 7) after treatment during the follow-up of 3–29 months (median 18). Conclusion : 3D conformal hypofractionated single high-dose radiotherapy of 48 Gy in 4 fractions using a stereotactic Body Frame was useful for the treatment of lung tumors.

  • Three-dimensional conformal radiotherapy for extracranial tumors using a stereotactic Body Frame
    Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 2001
    Co-Authors: Yasushi Nagata, Yoshiharu Negoro, Tetsuya Aoki, Takashi Mizowaki, Kenji Takayama, Masaki Kokubo, Norio Araki, Michihide Mitsumori, S. Yano, Yuko Koga
    Abstract:

    This paper was reviewed to evaluate the feasibility of three-dimensional (3-D) conformal radiotherapy for extracranial tumors, especially for solitary lung tumors using a stereotactic Body Frame. To extend the technique of stereotactic irradiation for intracranial tumors, accurate Body fixation and regulation of internal target motion are essential. In our study, a stereotactic Body Frame was used, and daily setup accuracy was verified. As a result, its setup accuracy was maintained within 0-8.5 mm (Ave=2.5mm). In our initial clinical experiences for thirty-two patients with 6-10 non-coplanar static beams, forty or 48 Gy was irradiated. During the follow-up of 4-27 (Average=11) months, twenty-nine (94%) tumors were locally controlled without any symptomatic complications. Recently, respiratory-gated irradiation systems, CT-linac systems, a real-time tumor tracking system, Cyber-knife, and C-arm linac were developed. With all these techniques, stereotactic irradiation for extracranial tumors are future direction of three-dimensional conformal radiotherapy.